International recognition for cancer researchers
Johanna Olweus and Erlend Strønen have published a new study in the journal Science. The article has attracted widespread international attention and was the subject of a separate commentary article in Science.
Erlend Strønen and Johanna Olweus are first and last author respectively of the study that was published in Science. Photo: Private
Professor Johanna Olweus, in collaboration with Ton Schumacher and Fridtjof Lund-Gundersen, all of whom are group leaders at the K.G Jebsen Centre for Cancer Immunotherapy, have published a study in Science. Doctor and researcher Erlend Strønen is first author of the study. This work shows that immune cells from healthy people can assist the immune defence system of cancer patients in fighting the disease. The concept implies that cancerous cells can be destroyed without causing any harm to normal cells, and this therapy is thus expected to have few adverse effects.
Commented upon in Science
The publication has attracted major international attention and has been commented upon in the journal Science: ’Outsourcing the immune response to cancer’. About the response to the recently published research results, Olweus says:
‘It’s overwhelming and fantastically inspiring. I hope to be able to help other researchers continue this work.’
The publication has been measured by Altmetric as ranking among the top five per cent of all research output in terms of international media coverage. The article was considered so important that Science asked for a commentary article to the publication. Olweus tells us the following:
‘What stirred most interest was the new opportunities that present themselves for using the immune response from a healthy donor to supplement the patient’s own weakened immune response to cancer.’
Professor Johanna Olweus heads the Immunotherapy and Antigen Presentation research group as well as the K.G. Jebsen Centre for Cancer Immunotherapy. Johanna Olweus is last author accompanied by Ton Schumacher, while Erlend Strønen is first author. The article published in Science bears the title: ’Targeting of cancer neoantigens with donor-derived T cell receptor repertoires